Ventaris Surgical Lands $30M to Reshape Kidney Stone Treatment

SAN CARLOS, CA – January 09, 2026 – Medical device innovator Ventaris Surgical, Inc. has successfully closed a $30 million Series A financing round to advance its next-generation system for kidney stone treatment. The substantial investment, led by Longitude Capital, signals strong investor confidence in the company's mission to solve one of the most persistent challenges in modern urology: achieving complete stone clearance.

The funding round also saw participation from new investor Vensana Capital and existing backers Atypical Ventures, Neotribe Ventures, and Boutique Venture Partners. The capital injection is earmarked to accelerate clinical development, navigate regulatory pathways, and prepare for the commercial launch of a technology poised to improve outcomes for millions of patients worldwide.

The Growing Challenge of an Ancient Ailment

Kidney stone disease, or nephrolithiasis, is a painful and increasingly common condition. Affecting up to 15% of the global population, its prevalence is on the rise, driven by factors including modern dietary habits, rising rates of obesity and diabetes, and even climate change. The global market for kidney stone management devices reflects this growing burden, valued at over $2.5 billion and projected to exceed $4 billion by 2034.

Modern urology offers several effective treatments, with ureteroscopy (URS) becoming a preferred minimally invasive procedure. During URS, a surgeon guides a thin, flexible scope through the urinary tract to visualize and treat stones directly. While highly effective, the procedure is not without its limitations. A significant unmet need, which Ventaris aims to address, is the difficulty of achieving a 100% stone-free state. Residual fragments, even microscopic ones, can serve as seeds for new stone formation, leading to recurrence and the need for repeat procedures.

Surgeons face numerous hurdles with current tools. The procedure demands intense focus and dexterity, and surgeon fatigue can become a factor in long or complex cases. Maintaining clear visibility while managing fluid irrigation to prevent high internal kidney pressure—a risk factor for postoperative complications like sepsis—adds another layer of complexity. Furthermore, the process of fragmenting a stone and retrieving all the pieces can create procedural bottlenecks, extending operating time.

A New Generation of Tools for a Persistent Problem

Ventaris Surgical was founded to address these specific challenges. The company is developing a novel ureteroscopic system designed from the ground up to streamline the procedure and empower surgeons to achieve more consistent and complete stone clearance. While specific details of the technology remain proprietary, the company's stated goal is to remove the inherent friction points that complicate current workflows.

"Kidney stone surgery demands an exceptional level of skill, focus, and persistence," said Surag Mantri, CEO of Ventaris Surgical. "Surgeons are often willing to invest the time and effort required to pursue complete stone clearance, but today's tools can make that goal difficult to achieve consistently. Ventaris was founded with the goal of removing unnecessary friction from the procedure, so that surgeons can focus their time and effort on reliably achieving complete stone clearance."

By creating a more efficient and reliable system, the technology promises a dual benefit: improving clinical outcomes for patients by reducing the risk of stone recurrence, and easing the physical and mental burden on the surgeons performing these delicate procedures.

Investor Confidence Signals a Market Shift

The $30 million financing is more than just capital; it is a significant endorsement from seasoned investors in the medical technology space. Lead investor Longitude Capital has a long history of backing transformative healthcare companies, with a portfolio that includes successes like Axonics and Procept BioRobotics. New investor Vensana Capital, with approximately $1 billion under management, is exclusively dedicated to partnering with entrepreneurs in the medtech sector.

"Ventaris' technology has the potential to both improve outcomes and reduce the burden on surgeons. Their approach resolves several critical unmet needs in today's standard of care," commented Maxwell Bikoff, Managing Director at Longitude Capital, highlighting the strategic alignment between the investors' philosophy and Ventaris's mission.

As part of the financing, the company's board will be strengthened by the addition of Varun Gupta of Longitude Capital and Justin Klein of Vensana Capital. Klein, a co-founder and Managing Partner at Vensana, brings a wealth of experience from his previous role leading medtech investing at NEA and has a deep track record of guiding innovative medical device companies to successful exits. Their inclusion, alongside independent board member Amir Abolfathi, provides Ventaris with a powerful combination of financial backing and strategic expertise.

Navigating a Competitive and Regulated Landscape

Ventaris enters a competitive but opportunity-rich market. The field of urological devices is dominated by established giants like Boston Scientific, Olympus, and Karl Storz, all of whom are actively innovating. Recent advancements from competitors include single-use digital ureteroscopes with integrated pressure monitoring and new thulium fiber laser systems designed for faster and more efficient stone fragmentation. To succeed, Ventaris must demonstrate that its system offers a distinct and superior advantage over these existing and emerging technologies.

The proceeds from the Series A round will be critical for this next phase. The company must now generate robust clinical data to prove its system's safety and efficacy. This data will form the basis of a submission to the U.S. Food and Drug Administration (FDA) for market clearance. Depending on the novelty of the device, this will likely follow either the 510(k) pathway, which requires demonstrating substantial equivalence to an existing device, or the more rigorous Pre-Market Approval (PMA) process for entirely new technologies.

With substantial funding and a board fortified with industry veterans, Ventaris Surgical is now well-positioned to navigate these clinical and regulatory hurdles. The company's progress will be closely watched by urologists, patients, and competitors alike, as its technology has the potential to set a new standard of care in the treatment of a condition that affects millions.